The Pakistan Drug Regulatory Authority (DRAP) ordered three pharmaceutical companies that withdraw the “deficient” medical devices of the market and advised pharmacists and chemicals to stop supplying these products.
“[The] The Central Drug Laboratory Karachi informed Pakistan’s drug regulatory authority that the samples of medical devices have been declared “deficient”, “said an alert issued by DRAP.
The alert identified the automatic zindagi 5 ml deactivation syringe, 5 ml ultra fine SMD syringe and Ultra fine SMD syringe without 3 ml pain as lower quality devices.
“The use of these syringes, in invasive or intravenous procedures, raises a significant risk of introducing microbial contaminants into the patient’s body, which can lead to localized infections, abscesses or systemic infections that threaten life, particularly in immunocompromised individuals,” Drap said.
“All pharmacists and chemicals who work in distribution and pharmacies must immediately verify their actions and stop supplying the mentioned products,” said the statement, added that the remaining actions must be forty and returned to the supplier or the company.
Zindagi’s automatic deactivation syringe declared himself “poor” on the basis of sterility test, while ultra fine SMD syringes declared themselves “deficient” on the basis of a sterility test and a description test with “clear black particles found in the syringe barrel.”
The alert advised consumers to stop using products with the number of lots affected and communicate with their doctor or medical care provider if they experience any problem that may be related to the use of articles. In addition, he urged the incident to DRAP.
Last year, in March, DRAP directed a pharmaceutical company to remember a syrup, which is given to children to treat fever, the market and advised health professionals not to prescribe it.
In January 2024, DRAP ordered the pharmaceutical companies to withdraw nine contaminated syrups, according to its executive director.
